# Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

> **NCT06932744** · PHASE3 · RECRUITING · sponsor: **Wuhan Createrna Science and Technology Co., Ltd** · enrollment: 66 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Haemoglobinuria (PNH)

## Interventions

- **DRUG:** MY008211A tablets
- **DRUG:** Eculizumab Injection

## Key facts

- **NCT ID:** NCT06932744
- **Lead sponsor:** Wuhan Createrna Science and Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06932744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06932744, "Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06932744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*